Paul Rosenberg, MD
Psychiatry · Baltimore, MDNPI 1942238563
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $57,309 of the $66,199 with a category attached, or 86.6%. 6 manufacturers reported payments, led by Novo Nordisk at 34.0% of the total. Among psychiatry clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $2546.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$22K
- Eli Lilly$15K
- Acadia Pharmaceuticals Inc$9K
- H. Lundbeck A S$7K
- Biogen$6K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
Across 68 payments — averaging $26,947 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Functional Neuromodulation Inc$947K
- Eli Lilly$458K
- Eisai Inc.$427K
What the payments were for
- Consulting fees$57,30987%
- Speaking & faculty fees$5,4008%
- Travel & lodging$2,6854%
- Food & beverage$8061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $22,488 |
| Eli Lilly | 4 | $15,135 |
| Acadia Pharmaceuticals Inc | 2 | $9,300 |
| H. Lundbeck A S | 5 | $6,746 |
| Biogen | 1 | $6,375 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $6,156 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$6,746
- NUPLAZID$5,700
- DISEASE EDUCATION$3,600
How this compares
$66,199 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 89 | $8,458 |
| Rivastigmine | 27 | $6,831 |
| Memantine Hcl | 94 | $3,784 |
| Donepezil Hcl | 155 | $2,543 |
| Escitalopram Oxalate | 82 | $1,184 |
| Mirtazapine | 36 | $686 |
| Divalproex Sodium | 15 | $669 |
| Olanzapine | 31 | $668 |
| Quetiapine Fumarate | 21 | $544 |
| Duloxetine Hcl | 19 | $539 |
| Methylphenidate Hcl | 33 | $404 |
| Sertraline Hcl | 32 | $307 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $233 |
| Trazodone Hcl | 41 | $223 |
| Buspirone Hcl | 16 | $222 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Baltimore
- John VaethBaltimore$2.1M
- Scott AaronsonBaltimore$334K
- Robert LehmanBaltimore$140K
- Karen AndersonBaltimore$117K
- Orlando DavisBaltimore$104K
- Akira SawaBaltimore$69K
- Adam KaplinBaltimore$62K
- Marc FishmanBaltimore$59K
- David NeubauerBaltimore$59K
- Chiadikaobi OnyikeBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.